Technology Transfer

Case Western Reserve University's Technology Transfer Office (TTO) serves our innovators with full-spectrum intellectual property services. For both faculty and students, we provide support for intellectual property and commercialization that spans the research & development continuum. We serve our researchers by assessing and building upon the commercial potential of new ideas and inventions.

Through interaction with our inventors, regional and national networks, including our affiliate healthcare systems, and potential commercial partners, we endeavor to determine the best path of translation and ultimate commercialization for University intellectual assets.

Consistent with the University's mission, the Technology Transfer Office is working towards enhancing its role in the promotion of an inclusive culture of global citizenship by exploring issues of access to essential medicines by resource-limited countries. This work includes moving towards the Universities Allied for Essential Medicine's Global Access Licensing Framework.

Recent News

Case Western Reserve ranks 21st in the world for U.S. utility patents
--CWRU Daily, June 15, 2021

PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
--PAVmed, June 10, 2021

NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer’s Disease Models
--NervGen, June 10, 2021

MedLumics Closes Upsized (21.7M USD) Financing Round and Appoints New Chairman
--MedLumics, May 28, 2021

PAVmed  Subsidiary  Lucid  Diagnostics Receives  CE  Mark  Certification  for  its EsoCheck®  Esophageal  Cell  Collection Device
--PAVmed, May 26, 2021

Please visit our TTO News webpage for more articles and press releases about TTO success stories.

For Questions About...

  • Your Invention Disclosure Form (IDF), please contact Joy Chen at 216.368.0362.
  • A Material Transfer Agreement (MTA) please contact Walid Jalabi at 216.368.2151.
  • A Data Use Agreement (DUA), please contact
  • Anything else, please contact Daniel Pendergast at 216.368.0184.